Trial
NCT05470985
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Crohn Disease
Intervention
Ozanimod
Why stopped
Study was terminated due to business reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-22